Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$79.95 USD

79.95
3,603,327

-0.74 (-0.92%)

Updated Aug 11, 2025 02:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mark Vickery headshot

Goldilocks Econ Data Presides Over Pre-Market

by Mark Vickery

We haven't thrown around the term "Goldilocks" too much lately, but this morning, the shoe fits.

Zacks Equity Research

Merck (MRK) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others

by Zacks Equity Research

Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.

Zacks Equity Research

Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?

by Zacks Equity Research

Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.

Zacks Equity Research

Why Merck & Co. (MRK) Might Surprise This Earnings Season

by Zacks Equity Research

Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Merck (MRK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends

by Kinjel Shah

J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.

Zacks Equity Research

Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Zacks Equity Research

Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWV

Zacks Equity Research

Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

by Zacks Equity Research

Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

Zacks Equity Research

Is Nuveen ESG LargeCap Value ETF (NULV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NULV

Zacks Equity Research

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $109.88, marking a -0.05% move from the previous day.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMV

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector

by Zacks Equity Research

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

Zacks Equity Research

Zacks Market Edge Highlights: Bank of America, Microsoft, Chevron, Merck and Marathon Digital

by Zacks Equity Research

Bank of America, Microsoft, Chevron, Merck and Marathon Digital are part of the Zacks Market Edge blog.

Tracey Ryniec headshot

Advice for Long-Term Stock Investors

by Tracey Ryniec

Thought long-term investing would be easy? Here's how to stay the course.

Zacks Equity Research

Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal

by Zacks Equity Research

Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.

Zacks Equity Research

Merck (MRK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $110.45 in the latest trading session, marking a -1.6% move from the prior day.

Zacks Equity Research

Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

Zacks Equity Research

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Zacks Equity Research

Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWV